Supernus Pharmaceuticals (SUPN) Cost of Revenue (2013 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Cost of Revenue data on file, last reported at $23.0 million in Q4 2025.

• Cost of Revenue for Q4 2025 came in at $23.0 million, down 11.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $74.6 million (down 4.29% YoY), and the FY2025 annual result was $74.6 million, down 4.29% from the prior year.
• Cost of Revenue advanced to $23.0 million in Q4 2025 per SUPN's latest filing, from $19.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $26.1 million in Q4 2024 and troughed at $15.0 million in Q1 2021.
• A 5-year average of $19.9 million and a median of $19.3 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2021 and 2024: Cost of Revenue surged 260.16% in 2021, then sank 30.48% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $17.0 million in 2021, then jumped by 35.07% to $23.0 million in 2022, then retreated by 14.49% to $19.6 million in 2023, then jumped by 32.97% to $26.1 million in 2024, then fell by 11.84% to $23.0 million in 2025.
• Business Quant data shows SUPN's Cost of Revenue at $23.0 million in Q4 2025, $19.0 million in Q3 2025, and $16.8 million in Q2 2025.